SAD, BAD Or DAD? Insiders See Risks Increasing In China IO Rush
This article was originally published in PharmAsia News
Executive Summary
More than 50 biotechs in China are now developing immuno-oncology assets centered mainly on the checkpoint inhibitor PD-1, meaning the emerging and promising treatment area is quickly becoming a crowded battlefield, insiders at a recent ChinaBio partnering event cautioned.